Mechanism: Reduce repetitive firing of neurons by stabilizing inactive sodium channels
Like Professor Galloway, five months into this year, I concur that GLP-1s are playing a role at re-shaping not just American health care, but society as well.
Dosing 3 days early creates significant overlap (approximately 60% of the previous dose remains when you add the new dose)
In October 2024, The US FDA Breakthrough Therapy designation is for the treatment of adults with non-cirrhotic metabolic dysfunction-associated steatohepatitis (MASH) and moderate or advanced fibrosis, based on survodutides groundbreaking results from Phase II study
01 Consultation Your journey begins with an in-depth consultation to evaluate your symptoms and determine if hormone pellet therapy is the right choice for you
Frankly, in routine clinical practice, optimal care just doesn't happen as consistently. If we're right, and these therapies are effective, you have at least a 50% chance of getting that treatment long before it's approved for use in type 1 diabetes